Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report.
Delayed methotrexate (MTX) elimination occurred in two patients with primary central nervous system lymphoma undergoing high-dose MTX treatment. Oral administration of the anion exchange resin colestimide, which binds MTX effectively in vitro, effectively accelerated MTX elimination. Colestimide probably interrupts the enterohepatic circulation, and is a potential oral antidote to MTX toxicity.
Makino
Keishi
K
Department of Neurosurgery, Kumamoto University School of Medicine, Japan. kmakino@fc.kuh.kumamoto-u.ac.jp
Kochi
Masato
M
Nakamura
Hideo
H
Kuroda
Jun-ichiro
J
Honda
Yoshiteru
Y
Ushio
Yukitaka
Y
Kuratsu
Jun-ichi
J
D000284:Administration, Oral; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D004811:Epichlorohydrin / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D012117:Resins, Synthetic / Q000008:administration & dosage / Q000494:pharmacology*
D000964:Antimetabolites, Antineoplastic; D007093:Imidazoles; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D008727:Methotrexate